病毒学
生物
背景(考古学)
接种疫苗
效价
抗体
冠状病毒
中和抗体
抗体效价
2019年冠状病毒病(COVID-19)
免疫学
病毒
传染病(医学专业)
医学
疾病
病理
古生物学
作者
И. В. Амосова,Т. А. Тимошичева,Renata A. Kadyrova,Yana Zabrodskaya,В С Вакин,Михаил Грудинин,V.V. Dzytseva,M.S. Khmelevsky,Dmitry Lioznov
出处
期刊:Virology
[Elsevier]
日期:2024-03-01
卷期号:: 110051-110051
标识
DOI:10.1016/j.virol.2024.110051
摘要
This research focuses on analyzing the dynamics of neutralizing antibody (nAbs) titers against type 5 adenovirus (Ad5) in the adult population of Russia following vaccination against the novel coronavirus infection with recombinant adenovirus type-5 COVID-19 vaccine (CanSino Biologics, China). The impact of the Ad5 vector on nAb titers was investigated using 302 blood serum samples from individuals who received a single dose of the Ad5-nCoV vector vaccine. The research revealed that 33.8% of adults in Russia had pre-existing anti-Ad5 nAbs before the pandemic. Notably, 40% of vaccinated individuals did not exhibit an increase in nAbs titers upon receiving the Ad5-based vaccine. However, in the group with no or low titers of anti-Ad5 nAbs (1:10–1:40), a significant 8-16-fold increase in nAb titers to Ad5 was observed.
科研通智能强力驱动
Strongly Powered by AbleSci AI